ABT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 15.48% compared to Abbott Laboratories's net margin of 11.12%. Abbott Laboratories's return on equity of 14.78% beat Boston Scientific's return on equity of 8.91%.

Abbott Laboratories has a consensus price target of $130.20, signalling upside risk potential of 12.96%. On the other hand Boston Scientific has an analysts' consensus of $99.14 which suggests that it could grow by 8.41%. Given that Abbott Laboratories has higher upside potential than Boston Scientific, analysts believe Abbott Laboratories is more attractive than Boston Scientific.

Abbott Laboratories has a beta of 0.727, which suggesting that the stock is 27.271% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Abbott Laboratories has a quarterly dividend of $0.55 per share corresponding to a yield of 1.91%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 62.14% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.6B, which are larger than Boston Scientific quarterly revenues of $4.2B. Abbott Laboratories's net income of $1.6B is higher than Boston Scientific's net income of $468M. Notably, Abbott Laboratories's price-to-earnings ratio is 35.04x while Boston Scientific's PE ratio is 75.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.89x versus 8.52x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 15.48% compared to Abbott Laboratories's net margin of 8.28%. Abbott Laboratories's return on equity of 14.78% beat Globus Medical's return on equity of 2.27%.

Abbott Laboratories has a consensus price target of $130.20, signalling upside risk potential of 12.96%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 11.62%. Given that Abbott Laboratories has higher upside potential than Globus Medical, analysts believe Abbott Laboratories is more attractive than Globus Medical.

Abbott Laboratories has a beta of 0.727, which suggesting that the stock is 27.271% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Abbott Laboratories has a quarterly dividend of $0.55 per share corresponding to a yield of 1.91%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 62.14% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.6B, which are larger than Globus Medical quarterly revenues of $625.7M. Abbott Laboratories's net income of $1.6B is higher than Globus Medical's net income of $51.8M. Notably, Abbott Laboratories's price-to-earnings ratio is 35.04x while Globus Medical's PE ratio is 126.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.89x versus 4.67x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 15.48% compared to Abbott Laboratories's net margin of 9.79%. Abbott Laboratories's return on equity of 14.78% beat Haemonetics's return on equity of 13.51%.

Abbott Laboratories has a consensus price target of $130.20, signalling upside risk potential of 12.96%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 40.52%. Given that Haemonetics has higher upside potential than Abbott Laboratories, analysts believe Haemonetics is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.727, which suggesting that the stock is 27.271% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Abbott Laboratories has a quarterly dividend of $0.55 per share corresponding to a yield of 1.91%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 62.14% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.6B, which are larger than Haemonetics quarterly revenues of $345.5M. Abbott Laboratories's net income of $1.6B is higher than Haemonetics's net income of $33.8M. Notably, Abbott Laboratories's price-to-earnings ratio is 35.04x while Haemonetics's PE ratio is 32.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.89x versus 2.98x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 15.48% compared to Abbott Laboratories's net margin of 1.94%. Abbott Laboratories's return on equity of 14.78% beat Masimo's return on equity of 5.75%.

Abbott Laboratories has a consensus price target of $130.20, signalling upside risk potential of 12.96%. On the other hand Masimo has an analysts' consensus of $172.77 which suggests that it could grow by 1.02%. Given that Abbott Laboratories has higher upside potential than Masimo, analysts believe Abbott Laboratories is more attractive than Masimo.

Abbott Laboratories has a beta of 0.727, which suggesting that the stock is 27.271% less volatile than S&P 500. In comparison Masimo has a beta of 1.010, suggesting its more volatile than the S&P 500 by 1.04%.

Abbott Laboratories has a quarterly dividend of $0.55 per share corresponding to a yield of 1.91%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 62.14% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $10.6B, which are larger than Masimo quarterly revenues of $504.6M. Abbott Laboratories's net income of $1.6B is higher than Masimo's net income of $9.8M. Notably, Abbott Laboratories's price-to-earnings ratio is 35.04x while Masimo's PE ratio is 117.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.89x versus 4.55x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.